Back

Aptevo’s mipletamig posts 93% clinical benefit rate in TP53-mutated AML

Verifying
  • Aptevo reported mipletamig triplet therapy benefit in frontline TP53-mutated AML patients.
  • 13 of 14 evaluable patients benefited; 11 achieved remission or remission with incomplete recovery.
  • Aptevo expects to complete RAINIER dose optimization by year-end and hold regulatory meetings in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Aptevo’s mipletamig posts 93% clinical benefit rate in TP53-mutated AML - CoinPost Terminal